The KAPARD guidelines for atopic dermatitis in children and adolescents:Part II. Systemic treatment, novel therapeutics, and adjuvant therapy
- Author:
Hwan Soo KIM
1
;
Eun LEE
;
Kyunghoon KIM
;
Taek Ki MIN
;
Dong In SUH
;
Yoon Ha HWANG
;
Sungsu JUNG
;
Minyoung JUNG
;
Young A PARK
;
Minji KIM
;
In Suk SOL
;
You Hoon JEON
;
Sung-Il WOO
;
Yong Ju LEE
;
Jong Deok KIM
;
Hyeon-Jong YANG
;
Gwang Cheon JANG
;
Author Information
- Publication Type:REVIEW
- From:Allergy, Asthma & Respiratory Disease 2025;13(1):3-11
- CountryRepublic of Korea
- Language:English
- Abstract: Atopic dermatitis is the most common chronic inflammatory skin disease in children and adolescents. The Korean Academy of Pediatric Allergy and Respiratory Disease published the Atopic Dermatitis Treatment Guideline in 2008, which has been helpful in atopic dermatitis treatment until now. Various reports on the development and effectiveness of new drugs have suggested that there is a need to develop and revise old treatment guidelines. Part 1 aimed to provide evidence-based recommendations for skin care management and topical treatment for atopic dermatitis. Part 2 focuses on systemic treatment, novel therapeutics, and adjuvant therapy. The goal of this guideline is intended to assist front-line doctors treating pediatric and adolescent atopic dermatitis patients make safer, more effective, and more rational decisions regarding systemic treatment, novel therapeutics, and adjuvant therapy by providing evidence-based recommendations with a clear level of evidence and benefit regarding treatment.
